Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in healthy volunteers
NCT06294288Phase 1Completed
- Sponsor
- LongBio Pharma
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of LP-003 in chronic spontaneous urticaria (CSU) (10 arms), sponsored by LongBio Pharma. Primary endpoint: Adverse Events at 280 days. Started Jul 2022; status: completed.
02
Drugs
LP-003
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06294288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294288.